- South Korea
- /
- Chemicals
- /
- KOSDAQ:A318000
The Trends At Korea Bio-GenLtd (KOSDAQ:318000) That You Should Know About
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. Having said that, from a first glance at Korea Bio-GenLtd (KOSDAQ:318000) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look.
Return On Capital Employed (ROCE): What is it?
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on Korea Bio-GenLtd is:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.13 = ₩3.7b ÷ (₩30b - ₩2.5b) (Based on the trailing twelve months to September 2020).
Therefore, Korea Bio-GenLtd has an ROCE of 13%. On its own, that's a standard return, however it's much better than the 8.0% generated by the Chemicals industry.
Check out our latest analysis for Korea Bio-GenLtd
While the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you're interested in investigating Korea Bio-GenLtd's past further, check out this free graph of past earnings, revenue and cash flow.
The Trend Of ROCE
Things have been pretty stable at Korea Bio-GenLtd, with its capital employed and returns on that capital staying somewhat the same for the last one year. Businesses with these traits tend to be mature and steady operations because they're past the growth phase. So unless we see a substantial change at Korea Bio-GenLtd in terms of ROCE and additional investments being made, we wouldn't hold our breath on it being a multi-bagger.
The Key Takeaway
In a nutshell, Korea Bio-GenLtd has been trudging along with the same returns from the same amount of capital over the last one year. Although the market must be expecting these trends to improve because the stock has gained 38% over the last year. However, unless these underlying trends turn more positive, we wouldn't get our hopes up too high.
If you'd like to know about the risks facing Korea Bio-GenLtd, we've discovered 3 warning signs that you should be aware of.
For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.
If you’re looking to trade Korea Bio-GenLtd, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if KBG might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About KOSDAQ:A318000
KBG
Produces and supplies a range of fine chemicals in South Korea and internationally.
Flawless balance sheet with proven track record.